Scotland-based biotech NuCana has announced that it is discontinuing its NuTide:323 study (NCT05678257).
NuTide:323 was an open-label, dose/schedule optimisation study evaluating the efficacy of NuCana’s NUC-3373 ProTide in combination with leucovorin, irinotecan and bevacizumab (NUFIRI+bev).
- NuCana plc's American Depositary Shares (ADSs) began trading on October 2, 2017.
- NuCana plc is a clinical-stage biopharmaceutical company that develops new medicines to treat cancer. The company was founded in 1997 by Hugh Stephen Griffith and Christopher Barry Wood and is headquartered in Edinburgh, Scotland. NuCana's ProTide technology transforms widely prescribed chemotherapy agents into safer and more effective medicines.
- GlobalData’s pharmaceutical database shows that NuCana has 13 ProTides in its drug development pipeline, in indications including ovarian cancer, non-small cell lung cancer, and acute lymphocytic leukaemia.
- https://www.nucana.com/
No comments:
Post a Comment